News

X-ZELL CEO presenting breakthrough CEC research at EMUC18

Amsterdam, November 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has used the 2018 European Multidisciplinary Congress on Urological Cancers (EMUC18) in Amsterdam as a platform to present new insights into the origin and clinical utility of Circulating Endothelial Cells...

X-ZELL taking centre stage at inaugural A*CCELERATE NOW expo

Singapore, November 2018 – X-ZELL Inc. has been one of eight promising biotechnology start-ups selected to exhibit at the inaugural A*CCELERATE NOW exhibition in Singapore. The landmark event – held in a move to celebrate the re-branding of ETPL, the commercialisation...

X-ZELL CEO to present at EMUC18 in Amsterdam

Amsterdam, November 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has been invited to join the 2018 European Multidisciplinary Congress on Urological Cancers (#EMUC18) in Amsterdam next month as a plenary speaker. Dr Bhakdi’s addition to the Congress’ high-profile program...

X-ZELL technology suite upgrade underway

Singapore, October 2018 – Cancer detection specialist, X-ZELL Inc., has announced a new version of the company’s world-unique Cryoimmunostaining™ suite. Whilst keeping details close to his chest, X-ZELL’s Head of Engineering & QA, Bart Van der Voort, revealed that...

More Bangkok hospitals embrace ground-breaking new liquid biopsy

Bangkok, October 2018 – Prostate cancer patients in Bangkok now have more access to state-of-the-art cancer detection technology than ever before. After debuting at Bangkok’s Chularat 9 Hospital at the end of 2017, X-ZELL Prostate™ – the first liquid biopsy based on...

X-ZELL officially incorporated in Singapore

Singapore, October 2018 – X-ZELL Inc., only recently named one of Asia’s 20 most innovative health tech start-ups, is coming to Singapore. According to X-ZELL CEO, Dr Sebastian Bhakdi, the rare cell detection specialist’s global head office is slated to move from...

X-ZELL among 16 most innovative health-tech start-ups in Asia

Singapore, September 2018 – Galen Growth, a Singapore-based analytics and advisory firm specialising in cutting-edge healthcare technology, has named X-ZELL Inc. as one of the 16 most innovative health technology start-ups in Asia. Selected to feature in the 2018...

X-ZELL technology featured in British urology journal

Oxford, August 2018 – X-ZELL Inc. CEO, Dr Sebastian Bhakdi, has published new research into the utility of tumour-derived Circulating Endothelial Cells (tCEC) for the detection of early-stage prostate cancer. His latest abstract – titled Tumor‐Derived Circulating...

X-ZELL launches global Cryoimmunostaining™ technology trial

Bangkok, July 2018 – After successfully completing a series of clinical trials across Southeast Asia, rare cell detection specialist X-ZELL Inc. is now making the company’s patented Cryoimmunostaining™ technology available to research organisations around the globe....

X-ZELL CEO to present at APCC 2018

Brisbane, July 2018 – X-ZELL Inc. CEO, Dr Sebastian Bhakdi, will use the upcoming Asia-Pacific Prostate Cancer Conference (APCC) in Brisbane next month as a platform to reveal “exciting new insights” into early prostate cancer detection. According to Dr Bhakdi, his...

Get in Touch

Use the form below to contact us for more information.

X-ZELL

FIGHTING CANCER,
ONE CELL AT A TIME.

© 2018 X-ZELL INC

Find Us

XZELL HQ